Connect with us

Global Trends and Politics

Zepbound Copycats Remain Online Despite FDA Ban

Published

on

Zepbound Copycats Remain Online Despite FDA Ban

Compounding Pharmacies Defy FDA Ban on Copycat Versions of Weight-Loss and Diabetes Drugs

This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly’s weight-loss drug Zepbound and diabetes drug Mounjaro. However, online, it doesn’t look like much has changed.

Popular websites like Amble, EllieMD, Willow, and Mochi Health are still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, like Ivim, have stopped taking new patients. Mochi Health, however, has no plans to stop, and neither do the four pharmacies it uses to supply patients with the medications. The company uses a network of about 500 providers to write prescriptions for weight-loss drugs, including compounded versions.

Personalization is Key

According to Mochi CEO Myra Ahmad, offering personalized versions of the drugs will keep the company out of the crosshairs. "It can be different dosing schedules … some patients prefer to go up in dosage much more slowly," she said. "Some patients like to mix a number of other medications into their compounded formulations, depending on the side effects that they’re having. Some patients have side effects with any additives and brand name formulations. Compounding really opens up the door for so much personalization."

What is Compounding?

Compounding is where pharmacies mix ingredients of a drug to create a specialized version for specific patients. Say someone is allergic to a dye in a branded medication or needs a liquid form and the main manufacturer only sells capsules. In that case, the patient can turn to a compounded version. When drugs are in short supply, they can be compounded in larger quantities to help fill the gap.

FDA Guidance

The FDA has been clear about what is and is not a copy. According to the agency, a copy is a product that has a dosage within 10% of the commercially available drug or combines two or more commercially available drugs. Mochi insists all of its prescriptions are personalized, including doses that differ from the standard Zepbound strengths. Other websites like EllieMD are advertising tirzepatide mixed with vitamin B12.

What’s Next?

The next two months will be informative. Mass compounding of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, needs to stop by the end of May, according to the FDA. Hims & Hers Health has already said it will stop selling commercially available doses of semaglutide when the time comes. Customers who have a personalized dosing regimen will be able to continue without any change.

Conclusion

The FDA’s ban on mass compounding of tirzepatide and semaglutide has left many pharmacists and patients in a difficult position. While some pharmacies like Mochi Health have found a way to continue offering personalized versions of the drugs, others like Ivim have stopped taking new patients. The next few months will be crucial in determining the future of compounding pharmacies and their role in the healthcare industry.

FAQs

Q: What is compounding?
A: Compounding is where pharmacies mix ingredients of a drug to create a specialized version for specific patients.

Q: Why are some pharmacies still offering copycat versions of Zepbound and Mounjaro?
A: Some pharmacies believe that offering personalized versions of the drugs will keep them out of the crosshairs.

Q: What is the FDA’s stance on compounding?
A: The FDA sees copies as products that have a dosage within 10% of the commercially available drug or combine two or more commercially available drugs.

Q: What happens if pharmacies continue to offer copycat versions of tirzepatide and semaglutide?
A: Pharmacies that continue to offer copycat versions of the drugs may be putting themselves at risk of legal action from the FDA and drug manufacturers.

Continue Reading

Global Trends and Politics

Worker Shortages and Immigration Policies: Shaping the 2025 Global Workforce

Published

on

Worker Shortages and Immigration Policies: Shaping the 2025 Global Workforce

In 2025, labor shortages are emerging as a defining feature of the global economy, particularly in developed nations. Demographic trends, such as aging populations and declining birth rates, are constricting the labor supply, while immigration policies are further influencing workforce dynamics.

United States: Immigration Policies Intensify Labor Constraints

In the United States, proposed immigration policies, including plans to deport up to one million undocumented migrants, are raising concerns about exacerbating existing labor shortages. Small businesses across various sectors are already reporting difficulties in hiring, and further reductions in the labor force could lead to increased wage inflation and hinder economic growth.

Europe: The Role of Foreign Workers in Economic Growth

Conversely, in the Eurozone, foreign workers have become pivotal in driving economic growth. According to a recent European Central Bank study, foreign labor accounted for approximately half of the labor force growth since the COVID-19 pandemic. These workers are increasingly filling higher-skilled positions, offsetting the negative effects of aging populations and low birth rates.

Global Implications: Balancing Labor Needs and Policy Decisions

The contrasting approaches highlight the delicate balance policymakers must strike between managing immigration and sustaining economic vitality. While restrictive immigration policies may address certain domestic concerns, they risk intensifying labor shortages and impeding growth. On the other hand, embracing foreign labor can alleviate workforce constraints but may face political resistance.

As nations navigate these challenges, the interplay between demographic trends and immigration policies will continue to shape the global labor market, influencing economic trajectories and workforce compositions in the years to come.

Continue Reading

Global Trends and Politics

Saudi Fund PIF Invests in Women’s Golf

Published

on

Saudi Fund PIF Invests in Women’s Golf

Saudi Arabia is deepening its investment in women’s professional golf. The Public Investment Fund, the sovereign wealth fund of Saudi Arabia, announced that it will become the title partner of five events that will take place on the Ladies European Tour. Terms of the deal were not disclosed.

The PIF Global Series

As part of this latest deal, the tour will revamp the five events, which will be collectively rebranded as the PIF Global Series. The events take place in Riyadh, Saudi Arabia; Seoul, South Korea; London; Houston; and Shenzhen, China. “PIF continues to be a catalyst for the growth of women’s sports, committed to delivering long-term transformative impact by inspiring and empowering female athletes at every level,” Alanoud Althonayan, head of events and sponsorships at PIF, said in a statement.

Tournament Format and Prize Pool

The revamped tournament format will feature team and individual competitions happening simultaneously. The Saudis are also injecting additional money into the prize pools, with a collective purse of $13 million across the five events. Alexandra Armas, CEO of the Ladies European Tour, said the partnership with PIF has helped raise the level of competition in the women’s game and gives players more opportunities to succeed on the world stage.

Saudi Arabia’s Investment in Sports

Saudi Arabia has been aggressively investing in professional sports in recent years as part of its vision to diversify the country’s economy away from oil. Despite the fact that Saudi Arabia has been slow to give Saudi women rights, those investments have included spending big money on international women’s sports. Last May, the fund signed a multi-year partnership with the WTA Tour, the women’s professional tennis organization, to grow the game and improve women’s benefits in the league. And in March, PIF announced it will fully fund the tour’s maternity fund, which would allow women to take up to a year of leave fully paid.

PIF’s Involvement in Men’s Golf

However, PIF’s foray into men’s golf has been more complicated. Nearly two years ago, PGA Tour Commissioner Jay Monahan and PIF Governor Yasir Al-Rumayyan appeared on CNBC, announcing a merger between LIV Golf and the PGA Tour. But that deal has yet to happen, despite the latest push by President Donald Trump to bring the two parties together.

Upcoming Events

The Aramco Korea Championship kicks off Friday in Seoul.

Conclusion

In conclusion, PIF’s investment in women’s golf is a significant step forward for the sport. The partnership with the Ladies European Tour will provide more opportunities for female athletes and help grow the game globally. With a collective purse of $13 million across the five events, the PIF Global Series is set to be an exciting and competitive tournament.

FAQs

Q: What is the PIF Global Series?

A: The PIF Global Series is a revamped series of five events on the Ladies European Tour, collectively rebranded and sponsored by the Public Investment Fund of Saudi Arabia.

Q: Where will the PIF Global Series events take place?

A: The events will take place in Riyadh, Saudi Arabia; Seoul, South Korea; London; Houston; and Shenzhen, China.

Q: What is the total prize pool for the PIF Global Series?

A: The collective purse for the five events is $13 million.

Q: What is PIF’s involvement in men’s golf?

A: PIF’s foray into men’s golf has been complicated, with a proposed merger between LIV Golf and the PGA Tour yet to happen.

Q: When does the Aramco Korea Championship take place?

A: The Aramco Korea Championship kicks off Friday in Seoul.

Continue Reading

Global Trends and Politics

Carvana Q1 2025 Earnings Report

Published

on

Carvana Q1 2025 Earnings Report

Introduction to Carvana’s First-Quarter Results

Vehicles are seen on display at a Carvana dealership in Austin, Texas, on Feb. 20, 2023.
Carvana’s first-quarter results easily topped Wall Street’s expectations as the company reported record sales driven by higher-than-expected industry demand amid fears of price increases due to automotive tariffs.

Carvana’s Performance

Carvana CEO and co-founder Ernie Garcia loosely addressed potential impacts of tariffs on the business, saying the company experienced "little gyrations" of demand that have since leveled off. He downplayed the idea that the levies would have any material impact on its business that the company can’t handle.
"I don’t think we have too much interesting there," Garcia said Wednesday during the company’s quarterly call, adding that pricing may increase and could potentially be beneficial for used car sales.

Impact of Tariffs on Used Car Sales

While the tariffs of 25% on new imported vehicles and many parts do not directly impact used car sales, changes in new vehicle prices, production and demand affect the used car market.
A closely watched barometer for used vehicle pricing jumped last month to its highest level since October 2023 as dealers and consumers rushed purchases amid fears of price hikes due to auto tariffs, Cox Automotive reported earlier Wednesday.

Financial Performance

Here’s how the company performed in the first quarter, compared with average estimates:

  • Earnings per share: $1.51 vs. 67 cents expected
  • Revenue: $4.23 billion vs. $3.98 billion expected
    The online used vehicle retailer reported a 46% increase in year-over-year sales during the first three months of the year to nearly 134,000 units. Carvana also reported records of net income of $373 million; adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, of $488 million; and operating income of $394 million.

Long-Term Objectives and Quarterly Guidance

The company said its net income benefitted from roughly from $158 million associated with positive changes in the fair value of its warrants to acquire common stock of Carvana partner Root auto insurance.
Revenue of $4.23 billion was up 38% year over year from $3.06 billion.
Carvana, which doesn’t typically provide detailed annual targets, on Wednesday also updated its long-term objectives and quarterly guidance.
Its second-quarter guidance includes a "sequential increase in both retail units sold and adjusted EBITDA," while the new "management objective" is to sell 3 million retail units per year at an adjusted EBITDA margin of 13.5% within five to 10 years.

Conclusion

"We are incredibly well positioned for the path ahead and have very clear visibility to even stronger financial performance, much larger scales, and even better customer experiences," Garcia said in a release.
Garcia told investors the goal is "very exciting and very achievable," while noting that the company will prioritize "growth over margin within reasonable margin ranges."
The company’s return to growth comes several years after concerns that Carvana was close to bankruptcy as it focused on growth and mismanaged inventories during the coronavirus pandemic in 2021 to 2022.
Since then, the company has benefitted from a years-long restructuring to lower costs and increase efficiency, including shares of the company increasing roughly 27% this year.

FAQs

Q: What were Carvana’s first-quarter earnings per share?
A: Carvana’s first-quarter earnings per share were $1.51, exceeding the expected 67 cents.
Q: How did Carvana’s revenue perform in the first quarter?
A: Carvana’s revenue was $4.23 billion, up 38% year over year from $3.06 billion.
Q: What is Carvana’s long-term objective?
A: Carvana’s new management objective is to sell 3 million retail units per year at an adjusted EBITDA margin of 13.5% within five to 10 years.
Q: How has Carvana’s stock performed this year?
A: Carvana’s shares have increased roughly 27% this year.

Continue Reading
Advertisement

Our Newsletter

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending